Private Equity in Heart Failure Care; Oral PCSK9 Inhibitor Wins; First Robotic TAVR
Recent developments of interest in cardiovascular medicine
Related Articles
Opinion | A Watershed Moment for Texas
The recent flood offers some tough lessons on disaster preparedness
Opinion | When Defending Science, Fight With Composure
Just like in medicine, panic never saved a life but steadiness can
Study Sheds New Light on Gabapentin Risks
Dementia incidence higher for younger chronic back pain patients prescribed gabapentin
Should Kennedy Kick His Alleged Tanning Bed Habit?
Sun-kissed skin isn’t worth the increased skin cancer risk, dermatologist says
Biomarker Testing in Advanced Cancer Still Lags Behind Guideline Recommendations
Only 35% of patients had any type of biomarker testing to guide use of targeted agents
Biomarker Testing in Advanced Cancer Still Lags Behind Guideline Recommendations
Only 35% of patients had any type of biomarker testing to guide use of targeted agents
Gender-Affirming Care for Minors in FTC’s Crosshairs
Detransitioners and their advocates made their case against doctors, medical societies
Jeffrey A. Berinstein, MD, on the Safety of Pre-Op Tofacitinib in Acute Severe UC
Despite numerous treatments for acute severe ulcerative colitis (ASUC) that effectively reduce both symptom severity and disease complications — including corticosteroids as the current standard…
Stress Testing Picks Up ‘Novel Risk Patterns’ in Stable CAD Patients: ISCHEMIA
Patients with abnormal findings had worse outcomes down the road. Still unknown is exactly how to modify that risk.
Opinion | It’s ‘Code Red’ for Medicaid
It’s too late to stop the ‘Big Beautiful Bill’ but it’s not too late to continue the fight